FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019496774> ?p ?o ?g. }

• W2019496774 endingPage "740" @default.
• W2019496774 startingPage "734" @default.
• W2019496774 abstract "Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one PTK (c-kit, platelet-derived growth factor receptors, c-abl, or abl-related gene) were treated with 400 mg of imatinib twice daily. One patient with metastatic acral lentiginous melanoma, containing the highest c-kit expression among all patients, had dramatic improvement on positron emission tomographic scan at 6 weeks and had a partial response lasting 12.8 months. The responder had a substantial increase in tumour and endothelial cell apoptosis at 2 weeks of treatment. Imatinib was fairly well tolerated: no patient required treatment discontinuation because of toxicity. Fatigue and oedema were the only grade 3 or 4 toxicities that occurred in more than 10% of the patients. Imatinib at the studied dose had minimal clinical efficacy as a single-agent therapy for metastatic melanoma. However, based on the characteristics of the responding tumour in our study, clinical activity of imatinib, specifically in patients with melanoma with certain c-kit aberrations, should be examined." @default.
• W2019496774 created "2016-06-24" @default.
• W2019496774 creator A5001494021 @default.
• W2019496774 creator A5011465880 @default.
• W2019496774 creator A5011748210 @default.
• W2019496774 creator A5021892503 @default.
• W2019496774 creator A5023081248 @default.
• W2019496774 creator A5026562050 @default.
• W2019496774 creator A5036547243 @default.
• W2019496774 creator A5042127830 @default.
• W2019496774 creator A5045026021 @default.
• W2019496774 creator A5053460346 @default.
• W2019496774 creator A5059536506 @default.
• W2019496774 creator A5060563693 @default.
• W2019496774 creator A5061118653 @default.
• W2019496774 creator A5063540389 @default.
• W2019496774 creator A5063689346 @default.
• W2019496774 creator A5067354658 @default.
• W2019496774 creator A5069230926 @default.
• W2019496774 creator A5076432829 @default.
• W2019496774 creator A5081648218 @default.
• W2019496774 creator A5087156478 @default.
• W2019496774 creator A5087385450 @default.
• W2019496774 date "2008-08-19" @default.
• W2019496774 modified "2023-10-08" @default.
• W2019496774 title "Phase II trial of imatinib mesylate in patients with metastatic melanoma" @default.
• W2019496774 cites W1963669837 @default.
• W2019496774 cites W1995930366 @default.
• W2019496774 cites W1996017770 @default.
• W2019496774 cites W2002374809 @default.
• W2019496774 cites W2015682571 @default.
• W2019496774 cites W2017021967 @default.
• W2019496774 cites W2029409133 @default.
• W2019496774 cites W2033989981 @default.
• W2019496774 cites W2050596106 @default.
• W2019496774 cites W2074239395 @default.
• W2019496774 cites W2079641245 @default.
• W2019496774 cites W2115811601 @default.
• W2019496774 cites W2126920848 @default.
• W2019496774 cites W2131174104 @default.
• W2019496774 cites W2139248078 @default.
• W2019496774 cites W2139524845 @default.
• W2019496774 cites W2142233858 @default.
• W2019496774 cites W2150501295 @default.
• W2019496774 cites W2156266404 @default.
• W2019496774 cites W2163188200 @default.
• W2019496774 cites W2425502429 @default.
• W2019496774 doi "https://doi.org/10.1038/sj.bjc.6604482" @default.
• W2019496774 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2528157" @default.
• W2019496774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18728664" @default.
• W2019496774 hasPublicationYear "2008" @default.
• W2019496774 type Work @default.
• W2019496774 sameAs 2019496774 @default.
• W2019496774 citedByCount "196" @default.
• W2019496774 countsByYear W20194967742012 @default.
• W2019496774 countsByYear W20194967742013 @default.
• W2019496774 countsByYear W20194967742014 @default.
• W2019496774 countsByYear W20194967742015 @default.
• W2019496774 countsByYear W20194967742016 @default.
• W2019496774 countsByYear W20194967742017 @default.
• W2019496774 countsByYear W20194967742018 @default.
• W2019496774 countsByYear W20194967742019 @default.
• W2019496774 countsByYear W20194967742020 @default.
• W2019496774 countsByYear W20194967742021 @default.
• W2019496774 countsByYear W20194967742022 @default.
• W2019496774 countsByYear W20194967742023 @default.
• W2019496774 crossrefType "journal-article" @default.
• W2019496774 hasAuthorship W2019496774A5001494021 @default.
• W2019496774 hasAuthorship W2019496774A5011465880 @default.
• W2019496774 hasAuthorship W2019496774A5011748210 @default.
• W2019496774 hasAuthorship W2019496774A5021892503 @default.
• W2019496774 hasAuthorship W2019496774A5023081248 @default.
• W2019496774 hasAuthorship W2019496774A5026562050 @default.
• W2019496774 hasAuthorship W2019496774A5036547243 @default.
• W2019496774 hasAuthorship W2019496774A5042127830 @default.
• W2019496774 hasAuthorship W2019496774A5045026021 @default.
• W2019496774 hasAuthorship W2019496774A5053460346 @default.
• W2019496774 hasAuthorship W2019496774A5059536506 @default.
• W2019496774 hasAuthorship W2019496774A5060563693 @default.
• W2019496774 hasAuthorship W2019496774A5061118653 @default.
• W2019496774 hasAuthorship W2019496774A5063540389 @default.
• W2019496774 hasAuthorship W2019496774A5063689346 @default.
• W2019496774 hasAuthorship W2019496774A5067354658 @default.
• W2019496774 hasAuthorship W2019496774A5069230926 @default.
• W2019496774 hasAuthorship W2019496774A5076432829 @default.
• W2019496774 hasAuthorship W2019496774A5081648218 @default.
• W2019496774 hasAuthorship W2019496774A5087156478 @default.
• W2019496774 hasAuthorship W2019496774A5087385450 @default.
• W2019496774 hasBestOaLocation W20194967741 @default.
• W2019496774 hasConcept C121608353 @default.
• W2019496774 hasConcept C126322002 @default.
• W2019496774 hasConcept C143998085 @default.
• W2019496774 hasConcept C2777583451 @default.
• W2019496774 hasConcept C2777658100 @default.
• W2019496774 hasConcept C2778715236 @default.
• W2019496774 hasConcept C2778729363 @default.
• W2019496774 hasConcept C2778820342 @default.
• W2019496774 hasConcept C3019892230 @default.

• next